otitis media with perforation treatment :: Article CreatorOtitis Media With Effusion In Under 12s
Why the committee made the recommendations
There was high quality evidence showing that parents often felt their and their child's views about their child's illness were not taken into consideration by healthcare professionals, and they and their child were not given a choice about their child's treatment but felt coerced into decisions. The committee, based on their knowledge and experience, also agreed that the experience of otitis media with effusion (OME) is often different for each child, and therefore it is crucial that any treatment decisions be made in the context of the child's experience of OME and any associated impact or concerns, the parents' or carers' knowledge and experience of their child, and the family's circumstances. Therefore, they recommended that health professionals always ask the child, their parents or carers about their experiences to understand the impact of the illness on the child and the family.
There was a lack of consensus in the evidence on the information content that should be provided to parents and carers. However, the committee agreed, based on their knowledge and experience, that parents need to understand OME and its impact on a child's wellbeing, and that if they do not then they may not be receptive to potential management options. Therefore, they recommended children, parents and carers be provided with such information so they can make informed choices about care.
Children who have OME without hearing loss do not need treatment. However, the committee felt that it was important to clarify why it is not needed to these children and their parents when explaining this to them, as it may be a source of confusion or anxiety. It was also agreed that it would be helpful to remind children, parents and carers that they can always return for more advice if they have concerns about hearing loss in future.
The committee agreed, based on their knowledge and experience, that information should be shared with children, parents and carers as soon as OME is confirmed, and before any management decisions are made, to empower them to be involved in their care.
In the committee's experience, information is mostly provided verbally in face-to-face settings, but they agreed that having information that parents and carers could refer to later would be helpful in answering any questions that arise, as well as for explaining OME to other family members, schools and nurseries. There was low-quality evidence on parents and carers' needs for detailed information in accessible formats. Therefore, the committee highlighted the most useful formats indicated by the evidence, along with formats they felt were beneficial from their experience.
The committee also considered low-quality evidence of parents reporting that they receive conflicting and confusing information from healthcare professionals, and low-quality evidence that information provided often included medical terms that were incomprehensible. Therefore, the committee agreed that information needs to be tailored to the children, parents or carers and should avoid medical terminology. The committee were aware that the 2021 NICE guideline on babies, children and young people's experience of healthcare includes more general recommendations about caring for children and young people and how to provide information to children, so included a cross reference to that guideline.
Based on their knowledge and experience, the committee agreed that parents and carers understanding the impact of OME is important for helping them understand the ways they can support their child while they are experiencing hearing loss. The committee listed some useful examples of interventions that could also be used in educational settings. The committee recognised that one of the biggest impacts of hearing loss on children is having limited receptivity to education, and agreed that support in educational settings should be thought of as part of the overall support given to children with OME.
In the committee's experience, parents and carers may change their minds about a chosen management decision, either because they want to try a different management option, or because they realise that a different option is better suited to their child. Therefore, they agreed giving opportunities to discuss and answer questions about treatment was important.
Because of the fluctuating nature of OME, management decisions may need to be reviewed or changed. Therefore, the committee agreed based on their knowledge and experience that healthcare professionals should inform the child, parents or carers about this, so that they are aware that it may happen and that it does not mean the previous treatment was the wrong choice.
There was some limited evidence that household smoking was not associated with development of OME. However, in the committee's experience, household smoking or passive smoking may increase the risk of developing OME. This is also mentioned in the NICE clinical knowledge summary for OME (2021). Regardless of any risk associated with OME, it is widely accepted that passive smoking can cause a range of diseases and health conditions, so it is good practice to avoid exposing children to tobacco smoke.
Drugs For Treatment Of Otitis Media
Are you searching for medications to treat 'Otitis Media'? Welcome to this section, which serves as a repository for medications that are relevant to the treatment of Otitis Media. The page includes both the generic and brand names and can be an invaluable resource for healthcare professionals and individuals who wish to get an insight on different medication options. Click on a medication below to view details including brand names, prices, dosages, side effects, and administration guidelines. Additionally, a FAQs section is available for each medication, addressing popular inquiries and providing deeper insights into its use for Otitis Media management. We recommend consulting your doctor to verify the information presented on this page or for any additional clarifications. Advertisement Brand Names and Generic Names of Drugs for Treatment of Otitis Media Amoxicillin Amoxicillin is a penicillin-like , β-lactam antibiotic. Trade Names : More... Amoxicillin and Clavulanate Potassium Amoxicillin and Clavulanate Potassium contains semisynthetic antibiotic amoxicillin and β-lactamase inhibitor, prescribed for lower respiratory infections, otitis media, sinusitis, urinary tract infections, and skin Structure infections. Advertisement Amoxicillin and Clavulanic acid Amoxicillin and Clavulanic acid is a combination of β-lactam antibiotic, and a β-lactamase inhibitor (potassium clavulanate) prescribed to treat infections of the ears, lungs, sinus, skin, and urinary tract. Azithromycin Azithromycin is a macrolide antibiotic used for various bacterial infections such as infections of the middle ear, throat, bronchus, sinuses, skin and soft tissue. Trade Names : More... Cefaclor Cefaclor is a cephalosporin antibiotic, prescribed for certain infection caused by bacteria such as pneumonia, ear, lung, skin, throat, and urinary tract infections. Trade Names : More... Advertisement Cefditoren Cefditoren is a third-generation cephalosporin antibiotic, prescribed for certain bacterial infections. Trade Names : Cefetamet Cefetamet is a cephalosporin antibiotic, prescribed for susceptible infections. Trade Names : More... Ceftriaxone Ceftriaxone is indicated for: Lower Respiratory Tract Infections Skin infections Urinary Tract Infections Pelvic Inflammatory Disease –infections related to the female genital tract Bacterial Septicemia-infection in the blood Bone and Joint Infections Meningitis Surgical Prophylaxis –To prevent infections during surgery . Trade Names : More... Cefuroxime Axetil Cefuroxime Axetil is a semi synthetic cephalosporin antibiotic, prescribed for different types of infections such as lung, ear, throat, urinary tract and skin. Trade Names : Clarithromycin Clarithromycin is a macrolide antibiotic, prescribed infections of the middle ear, tonsillitis, throat infections, laryngitis, bronchitis, pneumonia, and skin infections. Trade Names : More... Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole is a macrolide and sulfonamide antibiotic combination, prescribed for acute otitis media. Framycetin Framycetin is an amino glycoside anti-infective agent, prescribed for eye/ear infections. Trade Names : More... Hydrocortisone, Neomycin and Polymyxin Hydrocortisone, Neomycin and Polymyxin contains two antibiotics and a corticosteroid, prescribed for ear, eye and skin infections. Levofloxacin Levofloxacin is prescribed for treating certain bacterial infections, and preventing anthrax. Trade Names : More... Phenazone Phenazone, also called antipyrine, is used Orally to reduce fever and pain in conditions like migraine. Trade Names : Sultamicillin Sultamicillin is an antibiotic combination, prescribed for urinary tract infection, otitis media, and gonorrhea. Trade Names : Search for Drugs: For Related Medical Condition Suggested Readings on Otitis Media Ear Blockage / Wax Blockage Tinnitus is the perception of ringing, hissing, or other sound within the ears when no corresponding external sound is present. Ear converts sound waves into electrical impulses that are transmitted to the temporal lobe of the brain through the auditory nerve. It consists of outer, inner and middle sections. Hearing aid is an electronic device that helps people with hearing loss to hear more and communicate more effectively. Only 1 out of 5 people benefit from a hearing aid. Learn about the medical condition labyrinthitis which causes debilitating symptoms like vertigo and dizziness. Understand the causes and treatment approaches for labyrinthitis. Mastoiditis, infection of mastoid bone, results from spread of middle ear infection like bacterial infections, presenting with redness or swelling behind ear. Adenoidectomy is a surgery which involves removal of the adenoid gland, a mass of lymphoid tissue located at the back of the nose. Cholesteatoma is a benign cystic growth of the ear located behind the ear drum in the middle ear. It consists of dead skin cells and is pearly white in color. It occurs mostly as a complication of repeated middle ear infections. Stapedectomy is a middle ear surgery to treat deafness due to abnormal growth in one of the middle ear bones called the stapes, making it fixed and immobile. The stapes bone is removed and replaced with an implant.
Acute Otitis Media
1. Holstiege J, Garbe E: Systemic antibiotic use among children and adolescents in Germany: a population-based study. Eur J Pediatr 2013; 172: 787–95. CrossRef MEDLINE 2. Van Buchem FL, Dunk JH, van't Hof MA: Therapy of acute otitis media: myringotomy, antibiotics, or neither? A double-blind study in children. Lancet 1981; 2: 883–7. CrossRef MEDLINE 3. Lieberthal AS, Carroll AE, Chonmaitree T, et al.: The diagnosis and management of acute otitis media. Pediatrics 2013;131: e964–99. CrossRef MEDLINE 4. Uitti JM, Laine MK, Tahtinen PA, Ruuskanen O, Ruohola A: Symptoms and otoscopic signs in bilateral and unilateral acute otitis media. Pediatrics 2013; 131: e398–405. CrossRef MEDLINE 5. Tahtinen PA, Laine MK, Huovinen P, et al.: A placebo-controlled trial of antimicrobial treatment for acute otitis media. N Engl J Med 2011; 364: 116–26. CrossRef MEDLINE 6. Hoberman A, Paradise JL, Rockette HE, et al.: Treatment of acute otitis media in children under 2 years of age. N Engl J Med 2011; 364: 105–15. CrossRef MEDLINE PubMed Central 7. Stangerup SE, Tos M: Epidemiology of acute suppurative otitis media. Am J Otolaryngol 1986; 7: 47–54. CrossRef MEDLINE 8. Vergison A, Dagan R, Arguedas A, et al.: Otitis media and its consequences: beyond the earache. Lancet Infect Dis 2010; 10: 195–203. CrossRef MEDLINE 9. Taylor S, Marchisio P, Vergison A, et al.: Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis 2012; 54: 1765–73. CrossRef MEDLINE PubMed Central 10. Alpert HR, Behm I, Connolly GN, Kabir Z: Smoke-free households with children and decreasing rates of paediatric clinical encounters for otitis media in the United States. Tob Control 2011; 20: 207–11. CrossRef MEDLINE 11. Coker TR, Chan LS, Newberry SJ, et al.: Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review. JAMA 2010; 303: 2161–9. CrossRef MEDLINE 12. Casey JR, Adlowitz DG, Pichichero ME: New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 2010; 29: 304–9. MEDLINE 13. Heikkinen T, Block SL, Toback SL, Wu X, Ambrose CS: Effectiveness of intranasal live attenuated influenza vaccine against all-cause acute Otitis Media in children. Pediatr Infect Dis J 2013; 32: 669–74. CrossRef MEDLINE 14. American Academy of Pediatries Subcommittee on Management of Acute Otitis Media: Diagnosis and management of acute otitis media. Pediatrics 2004; 113: 1451–65. CrossRef MEDLINE 15. Bertin L, Pons G, d'Athis P, et al.: A randomized, double-blind, multicentre controlled trial of ibuprofen versus acetaminophen and placebo for symptoms of acute otitis media in children. Fundam Clin Pharmacol 1996; 10: 387–92. CrossRef MEDLINE 16. Coleman C, Moore M: Decongestants and antihistamines for acute otitis media in children. Cochrane Database Syst Rev 2008: CD001727. MEDLINE 17. Palva T, Pulkkinen K: Mastoiditis. J Laryngol Otol 1959; 73: 573–88. CrossRef MEDLINE 18. Van Zuijlen DA, Schilder AG, van Balen FA, Hoes AW: National differences in incidence of acute mastoiditis: relationship to prescribing patterns of antibiotics for acute otitis media? Pediatr Infect Dis J 2001; 20: 140–4. CrossRef MEDLINE 19. Van Buchem FL, Peeters MF, van 't Hof MA: Acute otitis media: a new treatment strategy. BMJ (Clin Res Ed) 1985; 290: 1033–7. CrossRef MEDLINE 20. Damoiseaux RA, van Balen FA, Hoes AW, Verheij TJ, de Melker RA: Primary care based randomised, double blind trial of amoxicillin versus placebo for acute otitis media in children aged under 2 years. BMJ 2000; 320: 350–4. CrossRef MEDLINE 21. Spiro DM, Tay KY, Arnold DH, et al.: Wait-and-see prescription for the treatment of acute otitis media: a randomized controlled trial. JAMA 2006; 296: 1235–41. CrossRef MEDLINE 22. Little P, Gould C, Williamson I, et al.: Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media. BMJ 2001; 322: 336–42. CrossRef MEDLINE 23. Glasziou PP, Del Mar CB, Sanders SL, Hayem M: Antibiotics for acute otitis media in children. Cochrane Database Syst Rev 2004: CD000219. MEDLINE 24. Bartlett JG: Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002; 346: 334–9. CrossRef MEDLINE 25. DeShazo RD, Kemp SF: Allergic reactions to drugs and biologic agents. JAMA 1997; 278: 1895–6. CrossRef MEDLINE 26. Rovers MM, Glasziou P, Appelman CL, et al.: Antibiotics for acute otitis media: a meta-analysis with individual patient data. Lancet 2006; 368: 1429–35. CrossRef MEDLINE 27. Tristram S, Jacobs MR, Appelbaum PC: Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 2007; 20: 368–89. CrossRef MEDLINE PubMed Central 28. Rubin LG: Prevention and treatment of meningitis and acute otitis media in children with cochlear implants. Otol Neurotol 2010; 31: 1331–3. CrossRef MEDLINE 29. Paradise JL: Short-course antimicrobial treatment for acute otitis media: not best for infants and young children. JAMA 1997; 278: 1640–2. CrossRef MEDLINE 30. McDonald S, Langton Hewer CD, Nunez DA: Grommets (ventilation tubes) for recurrent acute otitis media in children. Cochrane Database Syst Rev 2008: CD004741. MEDLINE 31. Lous J, Ryborg CT, Thomsen JL: A systematic review of the effect of tympanostomy tubes in children with recurrent acute otitis media. Int J Pediatr Otorhinolaryngol 2012; 75: 1058–61. CrossRef MEDLINE 32. Van den Aardweg MT, Schilder AG, Herkert E, Boonacker CW, Rovers MM: Adenoidectomy for otitis media in children. Cochrane Database Syst Rev 2010: CD007810. MEDLINE 33. Leach AJ, Morris PS, Mathews JD: Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population:a randomized controlled trial. BMC Pediatr 2008; 8: 23. CrossRef MEDLINE PubMed Central 34. Groth A, Enoksson F, Hermansson A, et al.: Acute mastoiditis in children in Sweden 1993–2007—no increase after new guidelines. Int J Pediatr Otorhinolaryngol 2011; 75: 1496–501. CrossRef MEDLINE 35. Paradise JL, Rockette HE, Colborn DK, et al.: Otitis media in 2253 Pittsburgh-area infants: prevalence and risk factors during the first two years of life. Pediatrics 1997; 99: 318–33. CrossRef MEDLINE 36. Principi N, Baggi E, Esposito S: Prevention of acute otitis media using currently available vaccines. Future Microbiol 2012; 7: 457–65. CrossRef MEDLINE 37. Eskola J, Kilpi T, Palmu A, et al.: Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403–9. CrossRef MEDLINE 38. Haggard M: Otitis media: prospects for prevention. Vaccine 2008; 26 (Suppl 7): G20–24. CrossRef MEDLINE 39. Post JC, Goessier MC: Is pacifier use a risk factor for otitis media? Lancet 2001; 357: 823–4. CrossRef MEDLINE 40. Azarpazhooh A, Limeback H, Lawrence HP, Shah PS: Xylitol for preventing acute otitis media in children up to 12 years of age. Cochrane Database Syst Rev 2011: CD007095. MEDLINE e1. Agrawal S, Husein M, MacRae D: Complications of otitis media: an evolving state. J Otolaryngol 2005; 34 Suppl 1: 33–39. MEDLINE e2. Schwartz RH, Schwartz DM. Acute otitis media: diagnosis and drug therapy. Drugs 1980; 19: 107–18. CrossRef MEDLINE e3. Appelmann C, Balen F, Lisdonk E, Weert H, Eizenga W: Otitis media acuta: NHG-standaard (eerste herziening). Huisarts Wet 1999: 362–6. E4. Scottish Intercollegiate Guidelines Network: Diagnosis and management of childhood otitis media in primary care. Guideline No 66 February 2003. In: Edinburgh CoPi (ed.): Edinburgh: Scottish Intercollegiate Guidelines Network; 2003. Www.Sign.Ac.Uk/pdf/qrg66.Pdf (last accessed on 5 February 2014) e5. Forgie S, Zhanel G, Robinson J. Management of acute otitis media. Paediatr Child Health 2009; 14: 457–64. MEDLINE e6. Leitlinie der Deutschen Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM) Ohrenschmerzen. AWMF-Register Nr. 053/009 Klasse S3. E7. Leitlinie Seromukotympanon der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Halschirurgie. AWMF-Register Nr. 017/004 Klasse S1. E8. Johnson DL, McCormick DP, Baldwin CD: Early middle ear effusion and language at age seven. J Commun Disord 2008; 41: 20–32. CrossRef MEDLINE e9. Kamtsiuris P, Atzpodien K, Ellert U, Schlack R, Schlaud M: Prevalence of somatic diseases in German children and adolescents. Results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007; 50: 686–700. CrossRef MEDLINE e10. Turner D, Leibovitz E, Aran A, et al.: Acute otitis media in infants younger than two months of age: microbiology, clinical presentation and therapeutic approach. Pediatr Infect Dis J 2002; 21: 669–74. CrossRef MEDLINE e11. Klein JO: Otitis media. Clin Infect Dis 1994; 19: 823–33. CrossRef MEDLINE e12. Casey JR, Pichichero ME: Changes in frequency and pathogens causing acute otitis media in 1995–2003. Pediatr Infect Dis J 2004; 23: 824–8. CrossRef CrossRef e13. Hildmann H: Akute Otitis media. In: Naumann HH, Helms, J, Herberhold, C (ed.): Oto-Rhino-Laryngologie in Klinik und Praxis. Heidelberg, New York: Thieme 1994; 582. E14. Pelton SI: Otoscopy for the diagnosis of otitis media. Pediatr Infect Dis J 1998; 17: 540–543; discussion 580. CrossRef MEDLINE e15. Helenius KK, Laine MK, Tahtinen PA, Lahti E, Ruohola A: Tympanometry in discrimination of otoscopic diagnoses in young ambulatory children. Pediatr Infect Dis J 2012; 31: 1003–6. MEDLINE e16. Laine MK, Tahtinen PA, Helenius KK, Luoto R, Ruohola A: Acoustic reflectometry in discrimination of otoscopic diagnoses in young ambulatory children. Pediatr Infect Dis J 2012; 31: 1007–11. MEDLINE e17. Hoberman A, Paradise JL, Reynolds EA, Urkin J: Efficacy of Auralgan for treating ear pain in children with acute otitis media. Arch Pediatr Adolesc Med 1997; 151: 675–8. CrossRef MEDLINE e18. Wollenberg B, Heumann H: Zenner HP (ed.): Praktische Therapie von HNO-Krankheiten. Stuttgart: Schattauer 2008; 90. E19. Marcy M, Takata G, Chan LS, et al.: Management of acute otitis media. Evid Rep Technol Assess (Summ) 2000: 1–4. E20. Rosenfeld R (ed.): Evidence-based Otitis media. 2nd edition. Canada: Hamilton, ON 2003; 28. E21. Kaleida PH, Casselbrant ML, Rockette HE, et al.: Amoxicillin or myringotomy or both for acute otitis media: results of a randomized clinical trial. Pediatrics 1991; 87: 466–74. MEDLINE e22. Piglansky L, Leibovitz E, Raiz S, et al.: Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children. Pediatr Infect Dis J 2003; 22: 405–13. CrossRef MEDLINE e23. Dagan R, Hoberman A, Johnson C, et al.: Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J 2001; 20: 829–37. CrossRef MEDLINE e24. Leibovitz E, Piglansky L, Raiz S, et al.: Bacteriologic and clinical efficacy of one day vs. Three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in children. Pediatr Infect Dis J 2000; 19: 1040–5. CrossRef MEDLINE e25. Fireman B, Black SB, Shinefield HR, et al.: Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J 2003; 22: 10–6. CrossRef MEDLINE e26. Ilicali OC, Keles N, Deger K, Savas I: Relationship of passive cigarette smoking to otitis media. Arch Otolaryngol Head Neck Surg 1999; 125: 758–62. CrossRef MEDLINE e27. Daly KA, Giebink GS: Clinical epidemiology of otitis media. Pediatr Infect Dis J 2000; 19: 31–6. CrossRef MEDLINE
Comments
Post a Comment